Sequoia Financial Advisors LLC Invests $473,000 in Koninklijke Philips (NYSE:PHG)

Sequoia Financial Advisors LLC acquired a new stake in Koninklijke Philips (NYSE:PHG) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 20,294 shares of the technology company’s stock, valued at approximately $473,000.

A number of other institutional investors have also made changes to their positions in PHG. Citigroup Inc. grew its holdings in Koninklijke Philips by 1.3% during the first quarter. Citigroup Inc. now owns 36,882 shares of the technology company’s stock valued at $1,126,000 after purchasing an additional 483 shares during the last quarter. Advisory Services Network LLC grew its stake in Koninklijke Philips by 28.7% in the 1st quarter. Advisory Services Network LLC now owns 2,226 shares of the technology company’s stock valued at $41,000 after buying an additional 496 shares during the last quarter. 1832 Asset Management L.P. raised its holdings in Koninklijke Philips by 1.1% in the 1st quarter. 1832 Asset Management L.P. now owns 56,735 shares of the technology company’s stock worth $1,708,000 after acquiring an additional 619 shares during the period. Cambridge Investment Research Advisors Inc. lifted its position in Koninklijke Philips by 3.2% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 22,616 shares of the technology company’s stock worth $451,000 after acquiring an additional 696 shares during the last quarter. Finally, Holderness Investments Co. lifted its position in Koninklijke Philips by 4.4% during the 2nd quarter. Holderness Investments Co. now owns 16,507 shares of the technology company’s stock worth $358,000 after acquiring an additional 697 shares during the last quarter. 13.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on PHG shares. BNP Paribas lowered Koninklijke Philips from an “outperform” rating to an “underperform” rating in a research note on Wednesday, February 7th. StockNews.com raised Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Koninklijke Philips presently has a consensus rating of “Moderate Buy” and an average price target of $19.00.

Koninklijke Philips Stock Performance

NYSE PHG opened at $20.15 on Thursday. Koninklijke Philips has a twelve month low of $17.75 and a twelve month high of $24.27. The company has a quick ratio of 0.78, a current ratio of 1.20 and a debt-to-equity ratio of 0.58. The stock has a market cap of $18.71 billion, a P/E ratio of -35.35, a PEG ratio of 1.06 and a beta of 0.88. The company’s 50-day simple moving average is $20.40 and its 200 day simple moving average is $20.85.

Koninklijke Philips (NYSE:PHG) last released its quarterly earnings data on Monday, January 29th. The technology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.47 billion. Koninklijke Philips had a positive return on equity of 14.17% and a negative net margin of 2.53%. As a group, research analysts forecast that Koninklijke Philips will post 1.53 earnings per share for the current fiscal year.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.